4D pharma PLC (LON:DDDD; NASDAQ:LBPS) said it will collaborate with Parkinson’s UK as it continues to advance into clinical trials a drug that treats neurodegenerative conditions such as Parkinson’s.
It is setting up a patient advisory board (PAB) with the non-profit group made up of people living with the disease that will provide a “valuable patient-centric perspective” on the potential treatment.
It will also focus on raising awareness of the issues people with Parkinson’s face with current treatment options.
“4D pharma selected to work with Parkinson’s UK to represent the patient community as the largest charitable funder of Parkinson’s research in Europe,” said Alex Stevenson, chief scientific officer.
“The contributions of our patient advisory board, with the support of Parkinson’s UK, will be vital to 4D pharma’s efforts to not only develop novel therapeutics for this devastating condition but also promote a dialogue and partnership with the Parkinson’s patient community.”
Working in the emerging area of the human microbiome (the bacteria that reside mainly in the gut), 4D has developed Live Biotherapeutics — products that contain live organisms such as human commensal bacteria.
Its work in neurodegenerative disease provides hope for the 145,000 people who are currently living with Parkinson’s in the UK.